DuPont Launches Liveo™ C6-8XX Liquid Silicone Rubber Series for Healthcare Applications

Rhea-AI Summary

DuPont (NYSE:DD) launched Liveo™ C6-8XX Liquid Silicone Rubber, a USP Class VI (C6) medical-grade, two-part LSR series for healthcare applications on Feb 3, 2026. The series offers improved rheology, lower viscosity, faster molding cycles, a pot life > three days, and five hardness grades (30–70 Shore A).

Designed for high heat stability, multiple sterilization methods and ISO 9001/14001/13485 manufacturing, the products meet USP Class VI, select EP, REACH SVHC (< 0.1% w/w) and ISO 10993 testing for non-implant and short-term implant components.

Positive

• USP Class VI medical-grade certification reported
• Improved rheology and lower viscosity enable faster, consistent molding
• Pot life >3 days for extended processing windows
• Five hardness grades spanning 30–70 Shore A
• Manufactured under ISO 9001/14001/13485 certifications

Negative

• Intended for non-implant and short-term implants (<30 days), not long-term implant applications

News Market Reaction

+1.96%

1 alert

+1.96% News Effect

On the day this news was published, DD gained 1.96%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Implant duration: less than 30 days Product count: 5 products Hardness range: 30 to 70 Shore A +5 more

8 metrics

Implant duration less than 30 days Intended for short-term human implantation

Product count 5 products Number of hardness options in C6-8XX LSR series

Hardness range 30 to 70 Shore A Material hardness options for Liveo™ C6-8XX LSR series

Pot life greater than three days Processing window for the new LSR series

REACH SVHC threshold < 0.1% w/w Compliance level for REACH SVHC requirements

USP Class USP Class VI Regulatory classification of the medical-grade LSR series

ISO standards ISO 9001, 14001, 13485 Manufacturing certifications for Liveo™ C6-8XX LSRs

ISO testing standard ISO 10993 Standard used for biocompatibility testing

Market Reality Check

Price: $45.31 Vol: Volume 3,505,776 vs 20-da...

normal vol

$45.31 Last Close

Volume Volume 3,505,776 vs 20-day average 4,853,364 shares ahead of this launch-focused news. normal

Technical Shares at $44.43 were trading above the 200-day MA of $33.76, near the $45.07 52-week high.

Peers on Argus

Sector peers like PPG, APD, IFF, LYB, and RPM showed modest positive moves, whil...

2 Up

Sector peers like PPG, APD, IFF, LYB, and RPM showed modest positive moves, while momentum scanner flagged ALB and SQM moving up, suggesting stock-specific rather than broad sector-driven dynamics for DD.

Historical Context

5 past events · Latest: Jan 28 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 28	Product launch	Positive	+0.0%	Launch of AmberLite™ FPA57 resin for organic acid purification.
Jan 26	Program announcement	Positive	+0.1%	Launch of 3rd Tyvek® Sustainable Healthcare Packaging Awards program.
Jan 21	Earnings call setup	Neutral	+2.6%	Announcement of timing for Q4 and full-year 2025 earnings call.
Jan 20	Board change	Positive	+2.6%	Appointment of D.G. Macpherson as independent board director.
Dec 05	Product expansion	Positive	+1.7%	Kevlar® EXO™ expanded into hard armor applications like helmets and plates.

Pattern Detected

Recent product and portfolio announcements have generally coincided with small positive price moves, with one stronger move on an earnings call scheduling update.

Recent Company History

Over the past few months, DuPont has issued several innovation and corporate updates. On Jan 28, 2026, the AmberLite™ FPA57 resin launch saw a modest 0.04% gain. A Tyvek® sustainable packaging awards announcement on Jan 26, 2026 coincided with a 0.14% rise. Scheduling the Q4 2025 earnings call on Jan 21, 2026 and a board appointment on Jan 20, 2026 each aligned with stronger 2.6% moves. A Kevlar® EXO™ expansion on Dec 5, 2025 preceded a 1.73% gain. Today’s healthcare LSR launch fits this pattern of incremental, product-focused news.

Market Pulse Summary

This announcement highlights DuPont’s expansion of its healthcare materials portfolio with the Liveo...

Analysis

This announcement highlights DuPont’s expansion of its healthcare materials portfolio with the Liveo™ C6-8XX LSR series, targeting short-term implants and non-implant medical devices under USP Class VI and ISO 10993 frameworks. Recent news flow has similarly emphasized product innovation and portfolio depth. Investors may watch upcoming Q4 2025 results, adoption of these certified materials in automated manufacturing, and any further regulatory or clinical validation that could reinforce DuPont’s position in medical-grade silicones.

Key Terms

liquid silicone rubber, usp class vi, rheology, biocompatibility, +3 more

7 terms

liquid silicone rubber technical

"DuPont ... announced the launch of Liveo™ C6-8XX Liquid Silicone Rubber (LSR)"

Liquid silicone rubber (LSR) is a pourable, two-part silicone compound that cures into a flexible, heat- and chemical-resistant rubber used for molded parts. Think of it like a liquid that sets into durable silicone kitchenware or medical tubing; it is prized for consistent quality, biocompatibility and precision molding. Investors care because LSR affects product performance, manufacturing speed, regulatory clearance and cost structure — factors that influence revenue, margins and supply-chain risk.

usp class vi regulatory

"a new USP Class VI (C6) series of medical-grade, two-part silicone"

USP Class VI is a set of lab tests defined by the United States Pharmacopeia that checks whether a material is safe to contact body tissues and fluids, including tests for irritation, toxicity and reaction when implanted. Investors care because passing these tests is often required for medical devices, drug packaging or surgical components to gain regulatory approval and customer trust — think of it as a crash‑test rating for materials intended to touch the human body.

rheology technical

"Featuring improved rheology and lower viscosity, these materials enable"

Rheology is the study of how materials flow and deform under force, covering liquids, creams, gels and soft solids. Investors care because a product’s rheology affects manufacturing consistency, shelf life, how a drug or cosmetic is applied or absorbed, and quality control costs—think of it like how ketchup’s thickness determines whether it pours smoothly or clogs a bottle, which can impact sales and regulatory approval.

biocompatibility medical

"Designed for high heat stability, sterilization via multiple methods and proven biocompatibility"

Biocompatibility is a measure of how well a medical material or device interacts with living tissue without causing harmful reactions, such as inflammation, toxicity, or rejection. For investors, it matters because strong biocompatibility speeds regulatory approval, lowers the risk of costly recalls or lawsuits, and increases patient and clinician acceptance — analogous to how a friendly guest makes a house more comfortable and welcome.

reach svhc regulatory

"complies with REACH SVHC (< 0.1% w/w) requirements, and tested according"

REACH SVHC stands for the European Union list of “Substances of Very High Concern” under the REACH chemical safety law. It is effectively a regulatory watch list of chemicals that may cause serious health or environmental harm; being listed can trigger testing, disclosure, use limits, or eventual bans. Investors care because inclusion can force product redesigns, supply-chain disruptions, added compliance costs, or write-downs—similar to a company suddenly facing a costly safety recall.

iso 10993 regulatory

"requirements, and tested according to ISO 10993 standards."

A family of international standards for testing whether materials and medical devices are safe to touch or put into the human body, covering chemical, biological and toxicological tests. Investors should care because meeting these standards is often required for regulatory approval and market access; think of it as a safety passport that reduces the risk of product recalls, delays, or extra testing that can affect costs and sales timelines.

iso 13485 regulatory

"LSRs are manufactured under ISO 9001, 14001 and 13485 certifications"

ISO 13485 is an international quality management standard for organizations that design, produce, or service medical devices. Think of it as a factory’s rulebook and checklist that helps ensure products are safe, consistently made, and meet regulatory rules worldwide. For investors, certification signals lower operational and regulatory risk, easier market access, and greater reliability of a company’s medical products and supply chain — similar to buying from a trusted, inspected supplier.

AI-generated analysis. Not financial advice.

Improved-rheology medical-grade LSR offers process flexibility for fabricating medical devices, including devices intended for implantation in humans for less than 30 days, as well as for non-implant applications

WILMINGTON, Del., Feb. 3, 2026 /PRNewswire/ -- DuPont (NYSE:DD) today announced the launch of Liveo^™ C6-8XX Liquid Silicone Rubber (LSR), a new USP Class VI (C6) series of medical-grade, two-part silicone elastomers engineered to meet the stringent requirements of medical device applications.

The Liveo^™ C6-8XX LSR series delivers precision, reliability and processing efficiency for healthcare applications, particularly medical device fabrication. Featuring improved rheology and lower viscosity, these materials enable faster and more consistent molding cycles, as well as processing flexibility, making them ideal for fully automated production environments.

Designed for high heat stability, sterilization via multiple methods and proven biocompatibility, the new LSR series supports the development of safe, high-quality, complex medical devices, including non-implant and short-term implant healthcare components. The series includes five products representing a range of hardnesses from 30 to 70 Shore A: Liveo^™ C6-830 LSR, Liveo^™ C6-840 LSR, Liveo^™ C6-850 LSR, Liveo^™ C6-860 LSR and Liveo^™ C6-870 LSR.

"DuPont^™ Liveo^™ C6-8XX Liquid Silicone Rubber has been engineered to provide flexibility and reliability for medical device manufacturers," said Mateo Chirinos Palacios, global product marketing manager for DuPont Healthcare Solutions. "With better flow during molding and a pot life of greater than three days, this new LSR series enables improved processability and more complex designs, among many other benefits."

The new medical-grade product series meets USP Class VI and select EP regulatory requirements, complies with REACH SVHC (< 0.1% w/w) requirements, and tested according to ISO 10993 standards. Liveo™ C6-8XX LSRs are manufactured under ISO 9001, 14001 and 13485 certifications to provide the highest quality and reliability for healthcare applications.

Supplied in convenient two-component kits, Liveo^™ C6-8XX Liquid Silicone Rubber materials complement precision molding and automated systems, helping OEMs achieve efficiency without compromising safety or performance.

To learn more about these new LSRs, including detailed product specifications, regulatory compliance information and processing guidelines, visit the DuPont^™ Liveo^™ C6-8XX Liquid Silicone Rubber web page, accessible via the "Medical Device Solutions" section of liveo.dupont.com.

About DuPont^™ Liveo^™
DuPont^™ Liveo^™ is a globally recognized leader in technology for a broad range of innovations supporting medical devices, biopharmaceutical processing and pharmaceutical solutions. Liveo^™ high-performance materials help create safer healthcare environments and protect the health of patients and healthcare providers worldwide. More information can be found at liveo.dupont.com.

About DuPont
DuPont (NYSE: DD) is a global innovation leader, providing advanced solutions that help transform industries and improve everyday life across our key markets of healthcare, water, construction, and transportation. More information about the company, its businesses and solutions can be found at www.dupont.com. Investors can access information included on the Investor Relations section of the website at investors.dupont.com.

DuPont™, the DuPont Oval Logo, and all trademarks and service marks denoted with ™, ^SM or ^® are owned by affiliates of DuPont de Nemours, Inc. unless otherwise noted.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dupont-launches-liveo-c6-8xx-liquid-silicone-rubber-series-for-healthcare-applications-302675282.html

SOURCE DuPont

FAQ

What is DuPont Liveo C6-8XX LSR and when was it launched (DD)?

Liveo C6-8XX is a USP Class VI two-part medical LSR series launched Feb 3, 2026. According to DuPont, it offers improved rheology, lower viscosity and a pot life greater than three days for medical device molding.

Which medical applications does Liveo C6-8XX (DD) support and what implant duration is specified?

Liveo C6-8XX supports non-implant and short-term implant medical components under 30 days. According to DuPont, it is engineered for devices intended for implantation less than 30 days and non-implant uses.

What product range and hardness options are available in Liveo C6-8XX from DuPont (DD)?

The series includes five products across 30 to 70 Shore A hardness. According to DuPont, the line comprises Liveo C6-830, C6-840, C6-850, C6-860 and C6-870 LSR grades.

How does Liveo C6-8XX improve manufacturing for medical device makers (DD)?

The materials deliver improved flow, lower viscosity and faster, more consistent molding cycles. According to DuPont, these properties support automated production and complex part designs while extending processing windows.

What regulatory and quality standards does DuPont say Liveo C6-8XX meets (DD)?

Liveo C6-8XX meets USP Class VI, select EP requirements, REACH SVHC <0.1% w/w and ISO 10993 testing. According to DuPont, the products are manufactured under ISO 9001, 14001 and 13485 certifications.